Shared on17 Aug 25Fair value Decreased 40%
A notable downward revision in forecasted revenue growth and a substantial decline in future P/E have driven analysts to lower their price target for Verrica Pharmaceuticals from $25.00 to $15.00. What's in the News Verrica Pharmaceuticals was notified by Nasdaq of non-compliance with the $1.00 minimum bid price requirement and faces potential delisting; the company has requested a hearing, which stays the suspension or delisting process.
Shared on01 Aug 25Fair value Increased 525%
The consensus analyst price target for Verrica Pharmaceuticals surged from $4.00 to $40.00, reflecting improved future valuation as evidenced by a slight decline in the forward P/E ratio. What's in the News Verrica received a Nasdaq delisting notice due to failure to maintain a $1.00 minimum bid price and subsequently effected a 1-for-10 reverse stock split to regain compliance; shares have been trading above $1.00 post-split and the company plans to request cancellation of the delisting hearing upon ten days' compliance.
Shared on17 Apr 25Fair value Decreased 44%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.